SCHEDULE: LifeSci Capital Discloses 7.9% Stake in KALA BIO

LifeSci Capital LLC and its managers, Andrew McDonald and Michael Rice, have reported a beneficial ownership of 7.9% in KALA BIO, Inc. common stock.

Summary

• LifeSci Capital LLC, a Delaware-based broker or dealer, along with its managers Andrew McDonald and Michael Rice, collectively reported beneficial ownership of 2,200,000 shares of KALA BIO, Inc. common stock.
• This ownership represents 7.9% of KALA BIO, Inc.'s outstanding common stock.
• The percentage is calculated based on 27,849,725 shares of Common Stock outstanding as of December 31, 2025, as per a prospectus filed by KALA BIO, Inc. on January 8, 2026.
• LifeSci Capital LLC holds sole voting and dispositive power over all 2,200,000 shares.
• Andrew McDonald and Michael Rice share voting and dispositive power over the 2,200,000 shares solely in their capacity as managers of LifeSci Capital LLC, disclaiming beneficial ownership except for any pecuniary interest.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a 13G is a routine disclosure, the establishment of a significant 7.9% stake by an institutional investor like LifeSci Capital LLC can be interpreted as a vote of confidence in KALA BIO, Inc., which is generally a positive signal for the market.

Positives

• Increased transparency regarding significant institutional ownership in KALA BIO, Inc.
• The filing indicates a notable institutional investor, LifeSci Capital LLC, has taken a substantial position in the company, potentially signaling confidence.

Negatives

• The filing itself does not contain any negative information; it is a routine disclosure of beneficial ownership.

Risks

• The filing does not explicitly mention specific risks related to KALA BIO, Inc. beyond the inherent market risks associated with holding common stock.

Future Outlook

The filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance from KALA BIO, Inc. or the reporting persons regarding future performance or strategy.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing indicates continued institutional interest in the biotechnology sector, specifically in KALA BIO, Inc. The acquisition of a significant stake by a broker-dealer like LifeSci Capital LLC suggests a potential belief in the company's long-term prospects or a strategic investment within the life sciences industry.

Comparison to Industry Standards

• A 7.9% stake by an institutional investor is a significant position, often indicating a strong conviction in the company's value proposition, which is common among specialized biotech funds or investment banks like LifeSci Capital LLC.
• While specific comparable companies or projects are not mentioned in the filing, such an ownership percentage is generally considered a substantial holding for a single entity in a publicly traded biotech firm, aligning with typical institutional investment strategies in the sector.

Stakeholder Impact

• Shareholders: Increased transparency regarding institutional ownership and potential validation of the company's value by a significant investor.
• Employees: No direct impact mentioned, but a strong institutional investor base can contribute to company stability.
• Customers/Suppliers/Creditors: No direct impact mentioned in this ownership disclosure.

Next Steps

• KALA BIO, Inc. will continue its operations and report financial results as per SEC regulations.
• LifeSci Capital LLC will continue to hold its stake and may adjust its position in future filings if its ownership percentage changes significantly.

Key Dates

Keywords

KALA BIO, LifeSci Capital, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Biotechnology, Equity Stake